Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PharoVax FMD
- Development stage
- Unknown
- Lead developer
- Pharos Vaccine
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PharoVax FMD (also known as PharoVax-FMD) is a bivalent recombinant protein oil vaccine developed by Pharos Vaccine for the prevention of foot-and-mouth disease (FMD) in pigs and cows. It targets FMD virus serotypes O and A, utilizing chimeric recombinant proteins as the active immunogen formulated in an oil adjuvant to induce active immunity. As a marker (DIVA) vaccine, it does not generate antibodies against non-structural proteins (NSP), allowing for the differential diagnosis between vaccinated and field-virus-infected animals. The vaccine has received regulatory approval in South Korea.
- Brand names
- PharoVax FMDPharoVax-FMD
- Other names
- FMD Vaccine파로박스 구제역
02
Targets
FMDV (Foot-and-mouth disease virus)
Beyond the preview
Go deeper on PharoVax FMD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharoVax FMD.